Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Macrogenics Inc
Macrogenics Inc_20100121
  

Macrogenics Inc patents

Recent patent applications related to Macrogenics Inc. Macrogenics Inc is listed as an Agent/Assignee. Note: Macrogenics Inc may have other listings under different names/spellings. We're not affiliated with Macrogenics Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Macrogenics Inc-related inventors




Date Macrogenics Inc patents (updated weekly) - BOOKMARK this page
08/03/17Her2/neu-specific antibodies and methods of using same
07/20/17Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
07/13/17Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
07/13/17Tri-specific binding molecules and methods of use thereof
06/08/17Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
05/18/17Cd3-binding molecules capable of binding to human and non-human cd3
01/26/17Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
12/08/16Covalent diabodies and uses thereof
11/17/16Deimmunized serum-binding domains and their use in extending serum half-life
10/06/16Antibodies with altered binding to fcrn and methods of using same
09/15/16Antibodies reactive with b7-h3 and uses thereof
09/08/16Her2/neu-specific antibodies and methods of using same
08/04/16Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
07/14/16Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof
07/07/16Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
06/09/16Covalent diabodies and uses thereof
05/12/16Her2/neu-specific antibodies and methods of using same
03/03/16Compound targeting il-23a and tnf-alpha and uses thereof
02/18/16Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
01/21/16Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
12/03/15Fcgammariib specific antibodies and methods of use thereof
12/03/15Fcgammariib specific antibodies and methods of use thereof
10/01/15Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
09/17/15Identification and engineering of antibodies with variant fc regions and methods of using same
09/17/15Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
06/25/15Deimmunized serum-binding domains and their use in extending serum half-life
06/18/15Bcr-complex-specific antibodies and methods of using same
01/22/15Fcgammariib-specific antibodies and methods of use thereof
11/06/14Antibodies reactive with b7-h3 and uses thereof
11/06/14Her2/neu-specific antibodies and methods of using same
11/06/14Combination of fcgammariib-specific antibodies and cd20-specific antibodies and methods of use thereof
09/11/14Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express b7-h3 and uses thereof
05/15/14Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting
05/15/14Combination therapy with mdm2 and efgr inhibitors
04/10/14Cd3-binding molecules capable of binding to human and non-human cd3
01/16/14Bcr-complex-specific antibodies and methods of using same
11/07/13Covalent diabodies and uses thereof
08/08/13Identification and engineering of antibodies with variant fc regions and methods of using same
06/13/13Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
11/22/12Antibodies reactive with b7-h3 and uses thereof
11/01/12Identification and engineering of antibodies with variant fc regions and methods of using same
10/25/12Humanized fc gamma riib-specific antibodies and methods of use thereof
10/18/12Engineering fc antibody regions to confer effector function
08/30/12Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
06/07/12Fcgammariib specific antibodies and methods of use thereof
05/03/12Animal model for toxicology and dose prediction
03/22/12Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
02/09/12T-cell receptor antibodies and methods of use thereof
01/12/12Fcgammariib specific antibodies and methods of use thereof
12/15/11Identification and engineering of antibodies with variant fc regions and methods of using same
10/06/11Identification and engineering of antibodies with variant fc regions and methods of using same
06/23/11Cd16a binding proteins and use for the treatment of immune disorders
06/09/11Dual expression vector system for antibody expression in bacterial and mammalian cells
05/19/11Bcr-complex-specific antibodies and methods of using same
04/28/11Her2/neu-specific antibodies and methods of using same
04/07/11Antibodies with altered binding to fcrn and methods of using same
12/23/10Kid3 and kid3 antibodies that bind thereto
12/23/10Humanized fc gamma riib-specific antibodies and methods of use thereof
08/05/10Engineering fc antibody regions to confer effector function
08/05/10Fcgammariib fusion proteins and compositions thereof
07/22/10Tes7 and antibodies that bind thereto
07/08/10Covalent diabodies and uses thereof
04/08/10Antibodies that bind to epha2 and methods of use thereof
01/21/10Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
12/31/09Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
Patent Packs
08/13/09Fcgammariib specific antibodies and methods of use thereof
07/30/09Combination of fcgammariib-specific antibodies and cd20-specific antibodies and methods of use thereof
06/25/09Compositions for the prevention and treatment of smallpox
04/16/09Identification and engineering of antibodies with variant heavy chains and methods of using same
04/09/09Fcgammariib specific antibodies and methods of use thereof
03/19/09Fcgammariib specific antibodies and methods of use thereof
03/19/09Fcgammariib specific antibodies and methods of use thereof
03/05/09Covalent diabodies and uses thereof
02/26/09Fcgammariib specific antibodies and methods of use thereof
01/21/10Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Macrogenics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Macrogenics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';